Treatment with BI 655064 (antagonistic anti-CD40 antibody) modulates clinical and biomarker parameters associated with rheumatoid arthritis (RA).S. Visvanathan, M. Ramanujam, C. Schoelch, P. Baum, R. Vinisko, R. Thiedmann, U. Müller-Ladner, S. Daniluk, R. Ptaszynski, S. Padula, J.S Fine, J. Steffgen. American College of Rheumatology, 2016.